Who Should Attend NeuroStar 360?
This educational event is designed for hospital administrators (including executives and Managed Care Directors) and physicians (including Medical Directors) who are considering adding NeuroStar TMS Therapy to the hospital network. Participants will be provided unique educational opportunities by an experienced faculty of TMS Therapy experts.
All trademarks are the property of Neuronetics, Inc.
*NeuroStar TMS Therapy® is indicated for the treatment of Major Depressive Disorder in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode.
In a randomized controlled trial, patients receiving active NeuroStar TMS Therapy were four times more likely to achieve remission compared to patients receiving sham treatment (P = 0.0173; odds ratio = 4.05)1
The most common side effect is pain or discomfort at or near the treatment site.2 These events are transient; they occur during the TMS treatment course and do not occur for most patients after the first week of treatment. NeuroStar TMS Therapy is contraindicated in patients with non-removable conductive metal in or near the head.
NeuroStar TMS Therapy is available by prescription only. For full prescribing and safety information, please visit www.NeuroStar.com or call Neuronetics Customer Service at 1-877-600-7555.
1) George, MS, et al. (2010). Daily Left Prefrontal Transcranial Magnetic Stimulation Therapy for Major Depressive Disorder A Sham-Controlled Randomized Trial. Arch Gen Psychiatry. 67(5): 507-516.
2) Janicak, PG, et al. (2008) Transcranial Magnetic Stimulation (TMS) in the Treatment of Major Depression: A Comprehensive Summary of Safety Experience from Acute and Extended Exposure and During Reintroduction Treatment. J Clin Psychiatry, 69(2):222-232.